Sunesis Pharmaceuticals Announces Oral Presentation on Vosaroxin at the 21st Congress of the European Hematology Association
May 19 2016 - 7:28AM
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced an oral
presentation on vosaroxin at the 21st Congress of the European
Hematology Association (EHA) to be held June 9-12, 2016 at the
Bella Center in Copenhagen, Denmark.
The details for the oral presentation are as
follows:
Date & Time: Saturday, June
11, 2016, 5:00 p.m. to 5:15 p.m. Central European
TimePoster Title: Phase I/II study of vosaroxin
and decitabine in newly diagnosed older patients (PTS) with acute
myeloid leukemia (AML) and high-risk myelodysplastic syndrome
(MDS)Abstract Number: S505Session
Title: New Compounds in AML
TreatmentLocation: Hall A3
The full abstract can be viewed here.
The company will also publish data that will be
on display as an E-poster:
Date & Time: Friday, June
10, 9:30 a.m. - Sunday, June 12, 11:00 a.m. Central European
TimePoster Title: Characterization of patients
with relapsed or refractory AML in continued follow-up after
treatment with vosaroxin/cytarabine vs placebo/cytarabine in the
VALOR trialAbstract Number:
E930Location: E-Poster Screens
The full abstract can be viewed here.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company focused
on the development and commercialization of new oncology
therapeutics for the potential treatment of solid and hematologic
cancers. Sunesis has built a highly experienced cancer drug
development organization committed to improving the lives of people
with cancer and is currently pursuing regulatory approval in Europe
for its lead product candidate, vosaroxin, for the treatment of
relapsed or refractory acute myeloid leukemia in patients aged 60
and older. In addition, the company is advancing its
kinase-inhibitor pipeline of novel targeted therapies into the
clinic.
For additional information on Sunesis, please
visit http://www.sunesis.com.
SUNESIS and the logos are trademarks
of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries:
David Pitts
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024
